SAVA · CIK 0001069530 · operating
Cassava Sciences is a clinical-stage biotechnology company headquartered in Austin, Texas, focused on developing therapies for neurodegenerative diseases. The company's primary therapeutic candidate is simufilam, a small molecule drug that has completed Phase 2 clinical testing. Additionally, Cassava Sciences is developing SavaDx, a blood-based biomarker diagnostic platform designed to detect Alzheimer's disease, which represents a potential complementary revenue stream through diagnostic applications.
The company operates with a lean organizational structure of approximately 30 full-time employees. As a pre-commercial clinical-stage entity, Cassava Sciences does not currently generate meaningful product revenues. The company was originally incorporated in Delaware in 1998 under the name Pain Therapeutics, Inc., before rebranding to Cassava Sciences in March 2019 to reflect its strategic shift toward neurodegenerative disease treatment. Cassava Sciences is publicly traded on the Nasdaq exchange.
Fiscal years are as reported by the company and may not align with the calendar year. For example, Apple's FY 2024 ends in September 2024.
| Fiscal Year | EPS Diluted | EPS Basic | YoY | |
|---|---|---|---|---|
| 2024 | $-1.46 | $-0.53 | +37.1% | |
| 2023 | — | $-2.32 | — | |
| 2022 | — | — | — | |
| 2021 | — | — | — | |
| 2020 | — | — | — | |
| 2019 | — | — | — | |
| 2018 | — | — | — | |
| 2017 | — | — | — | |
| 2016 | — | — | — | |
| 2015 | $-0.31 | $-0.31 | -14.8% | |
| 2014 | $-0.27 | $-0.27 | -137.5% | |
| 2013 | $0.72 | $0.73 | — | |
| 2012 | — | — | — | |
| 2011 | — | — | — |
| Report Date | Filed | Accession Number | |
|---|---|---|---|
| 2024-12-31 | 2025-03-03 | 0001437749-25-005919 | SEC ↗ |
| 2023-12-31 | 2024-02-28 | 0001437749-24-005894 | SEC ↗ |
| 2022-12-31 | 2023-02-28 | 0001069530-23-000009 | SEC ↗ |
| 2021-12-31 | 2022-03-01 | 0001069530-22-000011 | SEC ↗ |
| 2020-12-31 | 2021-03-23 | 0001069530-21-000020 | SEC ↗ |
| 2019-12-31 | 2020-03-26 | 0001069530-20-000009 | SEC ↗ |
| 2018-12-31 | 2019-03-29 | 0001069530-19-000019 | SEC ↗ |
| 2017-12-31 | 2018-02-06 | 0001069530-18-000004 | SEC ↗ |
| 2016-12-31 | 2017-03-07 | 0001069530-17-000008 | SEC ↗ |
| 2015-12-31 | 2016-03-03 | 0001069530-16-000052 | SEC ↗ |
| 2014-12-31 | 2015-02-18 | 0001069530-15-000003 | SEC ↗ |
| 2013-12-31 | 2014-02-05 | 0001069530-14-000004 | SEC ↗ |
| 2012-12-31 | 2013-02-08 | 0001193125-13-046147 | SEC ↗ |
| 2011-12-31 | 2012-02-09 | 0001193125-12-049361 | SEC ↗ |
| 2010-12-31 | 2011-02-03 | 0001193125-11-023306 | SEC ↗ |
| 2009-12-31 | 2010-02-01 | 0001193125-10-018161 | SEC ↗ |
| 2008-12-31 | 2009-02-13 | 0001193125-09-027574 | SEC ↗ |
| 2007-12-31 | 2008-02-13 | 0001193125-08-028925 | SEC ↗ |
| 2006-12-31 | 2007-02-26 | 0001193125-07-038974 | SEC ↗ |